Xoma Stock News

EMERYVILLE, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, announced today Owen Hughes, Executive Chairman, and Brad Sitko, Chief Investmen

EMERYVILLE, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, announced today that Owen Hughes, Executive Chairman, and Brad Sitko, Chief Inves

EMERYVILLE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improvi

Xoma (XOMA) delivered earnings and revenue surprises of -381.82% and 88.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

EMERYVILLE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improvi

EMERYVILLE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improving

While XOMA offers an investment into an important sector of healthcare, drug revenue royalties, the story is just beginning. From first glance, years of losses and flat revenues look poor, but somethi

Xoma (XOMA) delivered earnings and revenue surprises of 5.88% and 12.73%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Xoma (XOMA) delivered earnings and revenue surprises of 5.88% and 12.73%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -5.97% and 44.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the sto

EMERYVILLE, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash divi

EMERYVILLE, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improving human health, announced today its Chairman and Chief Executive Officer, Jim Neal, will present at Oppenheimer’s 32 nd Annual Healthcare Conference (virtual) on Thursday, March 17, 2022, at 12:40 PM ET.

EMERYVILLE, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA ), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improving human health, announced today its Chairman and Chief Executive Officer, Jim Neal, will present at Oppenheimer''s 32 nd Annual Healthcare Conference (virtual) on Thursday, March 17, 2022, at 12:40 PM ET. The presentation can be accessed at https://bit.ly/3truAX8 or by visiting the investor relations section of the Company''s website at www.xoma.com . A replay of the presentation will be available and archived on the site for 90 days after … Full story available on Benzinga.com

EMERYVILLE, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improvi

XOMA press release (XOMA): Q4 GAAP EPS of $1.67 misses by $0.60.Revenue of $35.94M (+30.2% Y/Y) beats by $0.8M.Ended 2021 with cash and restricted cash of $95.4 million and no debt…